You are here

uniQure

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Biopharma Dive

valoctocogene roxaparvovec

Flag link:

UniQure presses go on Huntington’s gene therapy trial

UniQure presses go on Huntington’s gene therapy trial

Pharmaforum

Huntington's disease

clinical trials

Flag link:

Why Novo Nordisk should buy Uniqure

Why Novo Nordisk should buy Uniqure

EP Vantage

Flag link:

UniQure stays a step ahead in hemophilia B

UniQure stays a step ahead in hemophilia B

Biopharma Dive

clinical trials

Flag link:

Why biotech companies are often at the whim of things they cannot control, in one chart

Why biotech companies are often at the whim of things they cannot control, in one chart

Stat

Flag link:

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Yahoo/Benzinga

Sangamo Therapeutics

Catalyst Biosciences

Reata Pharmaceuticals

Vertex Pharmaceuticals

Gilead Sciences

TRACON Pharmaceuticals

Sorrento Therapeutics

Flag link:

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report

Endpoints

Flag link:

UniQure snags patents on Huntington's gene therapy as it preps for the clinic

UniQure snags patents on Huntington's gene therapy as it preps for the clinic

Biopharma Dive

Huntington's disease

clinical trials

Flag link:

This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why

This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why

Investors Business Daily

Spark Therapeutics

Flag link:

Uniqure turns the screw on Spark and Pfizer

Uniqure turns the screw on Spark and Pfizer

EP Vantage

Spark Therapeutics

Flag link:

UniQure’s hemophilia B gene therapy achieves 31% FIX activity

UniQure’s hemophilia B gene therapy achieves 31% FIX activity

Fierce Biotech

Flag link:

Who will pay for CRISPR?

Who will pay for CRISPR?

Stat

Spark Therapeutics

Flag link:

Biotech firm pulls pioneering gene therapy due to no demand

Biotech firm pulls pioneering gene therapy due to no demand

Yahoo/Reuters

Flag link:

Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark

Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark

Fierce Biotech

Spark Therapeutics

Flag link:

Positive hemophilia B gene-therapy results boost UniQure stock

Positive hemophilia B gene-therapy results boost UniQure stock

BioPharma Dive

Flag link:

UniQure's Gene Therapy Boosts Clotting in Two Hemophiliacs

UniQure's Gene Therapy Boosts Clotting in Two Hemophiliacs

Bloomberg

Flag link:

Positive Topline Results Announced From Phase I/II Trial in Sanfilippo B Syndrome Patients Using uniQure's Novel AAV5-Based Gene Therapy

Positive Topline Results Announced From Phase I/II Trial in Sanfilippo B Syndrome Patients Using uniQure's Novel AAV5-Based Gene Therapy

Yahoo

Flag link:

FDA demands another study for uniQure's ultra-pricey gene therapy

FDA demands another study for uniQure's ultra-pricey gene therapy

BioPharma Dive

lipoprotein lipase deficiency

Flag link:

The 5 Most Expensive Drugs in the World in 2015

The 5 Most Expensive Drugs in the World in 2015

Motley Fool

Flag link:

UniQure plans $100M follow-on offering in afterglow of big-ticket Bristol deal

UniQure plans $100M follow-on offering in afterglow of big-ticket Bristol deal

Fierce Biotech

Bristol-Myers Squibb

Flag link:

Pages